Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021
December 06, 2021 13:49 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021
December 06, 2021 06:30 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab
November 29, 2021 16:05 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021
November 22, 2021 17:05 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene to Participate in Upcoming Investor & Industry Conferences in November
November 09, 2021 16:05 ET
|
Adagene, Inc.
SAN DIEGO and SUZHOU, China, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting
November 04, 2021 09:24 ET
|
Adagene, Inc.
- Presentations demonstrate compelling preclinical differentiation of an anti-CD47 antibody and a CD20xCD3 bispecific T-cell engager, both leveraging SAFEbody™ technology - - Both candidates designed...
Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore
October 27, 2021 07:00 ET
|
Adagene, Inc.
- Phase 1b/2 trial to be conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in Collaboration with the Singapore Translational Cancer Consortium...
天演宣布出席杰富瑞（Jefferies）中国生物科技线上峰会
October 21, 2021 08:00 ET
|
Adagene, Inc.
中国苏州和美国旧金山, Oct. 21, 2021 (GLOBE NEWSWIRE) -- 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布，天演联合创始人、首席执行官兼董事长罗培志博士将参加2021年10月...
Adagene to Participate in the Jefferies Virtual China Biotech Summit
October 21, 2021 08:00 ET
|
Adagene, Inc.
SAN FRANCISCO and SUZHOU, China, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the...
天演藥業宣佈與 Exelixis 簽訂合作許可協議，共同開發具有更佳安全性和有效性的原創新型安全抗體偶聯藥物
February 03, 2021 08:24 ET
|
Adagene, Inc.
美國加州阿拉米達、加州三藩市及中國蘇州, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Exelixis, Inc. (Nasdaq: EXEL) 與天演藥業今日宣佈，雙方達成一項合作許可協議。根據該協議，Exelixis 將使用天演藥業自主研發及擁有精準掩蔽功能的安全抗體技術，共同開發 Exelixis...